UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION~~

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of ~~The Securities Exchange Act of 1934~~

~~Date~~The ofSecurities ~~Report~~Exchange ~~(Date~~Act of ~~earliest event reported): July 20, 2018~~1934

Date of Report (Date of earliest event reported): July 30, 2018

SteadyMed Ltd.

(Exact name of registrant as specified in its charter)

Israel	001-36889	Not applicable
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdiction of	(Commission File Number)	(IRS Employer
incorporation)		Identification No.)

5 Oppenheimer Street Rehovot 7670105, Israel ~~(Address of principal executive offices, including zip code)~~

~~925-272-4999~~ (~~Registrant’s~~Address ~~telephone~~of ~~number~~principal executive offices, including ~~area~~zip code)

~~N/A (Former name or former address, if changed since last report)~~925-272-4999

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§17 CFR 230.405 ~~of this chapter~~) or Rule 12b-2 of the Securities Exchange Act of 1934 (§17 CFR 240.12b-2 ~~of this chapter~~).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 85.0107. ~~Other~~Submission ~~Events~~of Matters to a Vote of Security Holders.

On July 2030, 2018, SteadyMed Ltd. (the “Company”) ~~and~~held ~~United~~an ~~Therapeutics~~extraordinary ~~Corporation~~general meeting of its shareholders (the “~~United~~Meeting”). ~~issued~~The arequired ~~joint~~quorum ~~press~~was ~~release~~present. ~~announcing~~The ~~the~~following ~~termination~~is a summary of the ~~waiting~~proposals ~~period~~and ~~under~~the voting results from the ~~Hart-Scott-Rodino~~Meeting. ~~Antitrust~~A ~~Improvement~~complete ~~Acts~~description of ~~1976~~each ~~relating~~matter tois ~~United’s~~described ~~previously~~in ~~announced~~more ~~acquisition~~detail ofin the Company.’s Adefinitive ~~copy~~proxy ofstatement filed with the ~~joint~~Securities ~~press~~and ~~release~~Exchange isCommission ~~attached~~on ~~hereto~~June 25, 2018, as ~~Exhibit~~supplemented by the definitive additional materials filed with the Securities and Exchange Commission on June ~~99.1~~29, 2018 and isJuly 16, ~~incorporated~~2018 ~~herein~~(together, bythe ~~reference~~“Proxy Statement”).

~~Item~~Proposal 91 — Approval of the Agreement and Plan of Merger and the Merger.01 The Company’s shareholders approved the Agreement and Plan of Merger, dated as of April 29, 2018, by and among the Company, United Therapeutics Corporation, and Daniel 24043 Acquisition Corp. ~~Financial~~Ltd. ~~Statements~~(the “Merger Agreement”), the terms of the merger contemplated thereby, and ~~Exhibits~~all other documents, agreements and transactions contemplated under or related thereto, including the Contingent Value Rights Agreement attached thereto and the warrant amendments between Messrs. Brian J. Stark, Keith Bank, Ron Ginor, each a director of the Company, and/or their affiliates, and the Company. The voting results are as follows:

(d) Exhibits.

For		Against		Abstain
20,917,435		62,240		1,286

~~99.1~~As ~~Joint~~required ~~Press~~by ~~Release~~the ~~dated~~Israeli ~~July~~Companies 20Law, ~~2018~~this ~~issued~~proposal received a majority of the votes of the shareholders, excluding abstentions, present at the Meeting in person or by proxy (i) who are not United Therapeutics Corporation ~~and~~or ~~SteadyMed~~Daniel 24043 Acquisition Corp. Ltd. (or any other person who holds 25% or more of the means of control of Daniel 24043 Acquisition Corp.) or anyone acting on their behalf (including relatives or corporations controlled by such persons) and (ii) who do not have a “Personal Interest” (as described in the Proxy Statement) in Proposal 1.

~~SIGNATURES~~Proposal 2 — Golden Parachute Payments. The Company’s shareholders approved, on a non-binding, advisory basis, certain compensation that will be paid or may become payable to the Company’s named executive officers in connection with the transactions contemplated by the Merger Agreement and ancillary agreements. The voting results are as follows:

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

For		Against		Abstain
17,905,155		2,585,741		490,065

	STEADYMED LTD.
	By:	/s/ David W. Nassif
Date: July 20, 2018		David W. Nassif
		Executive Vice President and Chief Financial Officer

2SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		STEADYMED LTD.


	By:	/s/ David W. Nassif
Date: August 1, 2018		David W. Nassif
		Chief Financial Officer

Filing Compare · SteadyMed Ltd.